Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.

AIDS (London, England) - 11 Sept 2006

Bonjoch Anna, Negredo Eugenia, Puig Jordi, Erkizia Itziar, Puig Teresa, Cabrera Cecilia, Ruiz Lidia, Clotet Bonaventura

Abstract excerpt

The aim of this pilot study was to assess whether enfuvirtide can be discontinued in patients on long-term viral suppression. Eight patients with multidrug-resistant virus were randomly assigned to stop and 10 subjects to continue enfuvirtide. At week 48, viral rebound occurred in five (62.5%) and in no patients, respectively, (P = 0.007). The CD4 cell decrease in failure patients was 5% (P = ns). These results...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP-ribosyl Cyclase 1
Share to CD4 Lymphocyte Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CD8-Positive T-Lymphocytes

Share to Enfuvirtide

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to Pilot Projects

Source

Identifiers

PMID: 16954734
DOI: 10.1097/01.aids.0000244212.15951.2b

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.PMID 16954734Read ↗

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.Semantic proximity Read ↗

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.Semantic proximity Read ↗

A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.Semantic proximity Read ↗

Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.Semantic proximity Read ↗

Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.Semantic proximity Read ↗

HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count.Semantic proximity Read ↗

Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy.Semantic proximity Read ↗

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).Semantic proximity Read ↗

Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations.Semantic proximity Read ↗

Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.Semantic proximity Read ↗

Early virological failure with a combination of tenofovir, didanosine and efavirenz.Semantic proximity Read ↗

Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.